Updates on Hirsutism: A Narrative Review

Ramadan S. Hussein, Walid Kamal Abdelbasset

International Journal of Biomedicine. 2022;12(2):193-198.
DOI: 10.21103/Article12(2)_RA4
Originally published June 5, 2022


Hirsutism is described as an abnormal amount of hair development in females in a male-like way. Excessive hair growth is frequently associated with severe emotional discomfort. Hirsutism is a frequent presentation to dermatologists, as women seek both aesthetic and therapeutic treatment options for their condition. Hirsutism is caused by an excess of androgens, most frequently from the ovary or adrenal glands. Hirsutism is frequently linked with metabolic disorders such as polycystic ovary syndrome (PCOS); it can also occur idiopathically, as a side effect of medicine, or, rarely, due to a serious underlying condition. This article discusses the diagnosis and treatment of hirsutism concisely.

polycystic ovary syndrome • hirsutism • treatment
  1. FERRIMAN D, GALLWEY JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961 Nov;21:1440-7. doi: 10.1210/jcem-21-11-1440. 
  2. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981 Aug 1;140(7):815-30. doi: 10.1016/0002-9378(81)90746-8.
  3.  Gruber DM, Berger UE, Sator MO, Horak F, Huber JC. Computerized assessment of facial hair growth. Fertil Steril. 1999 Oct;72(4):737-9. doi: 10.1016/s0015-0282(99)00333-7. 
  4. Mofid A, Seyyed Alinaghi SA, Zandieh S, Yazdani T. Hirsutism. Int J Clin Pract. 2008 Mar;62(3):433-43. doi: 10.1111/j.1742-1241.2007.01621.x.
  5. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev. 2000 Aug;21(4):347-62. doi: 10.1210/edrv.21.4.0401. 
  6. Himelein MJ, Thatcher SS. Polycystic ovary syndrome and mental health: A review. Obstet Gynecol Surv. 2006 Nov;61(11):723-32. doi: 10.1097/01.ogx.0000243772.33357.84. 
  7. Barth JH, Catalan J, Cherry CA, Day A. Psychological morbidity in women referred for treatment of hirsutism. J Psychosom Res. 1993 Sep;37(6):615-9. doi: 10.1016/0022-3999(93)90056-l. 
  8. Akiyama M, Smith LT, Holbrook KA. Growth factor and growth factor receptor localization in the hair follicle bulge and associated tissue in human fetus. J Invest Dermatol. 1996 Mar;106(3):391-6. doi: 10.1111/1523-1747.ep12343381. 
  9. Hawryluk EB, English JC 3rd. Female adolescent hair disorders. J Pediatr Adolesc Gynecol. 2009 Aug;22(4):271-81. doi: 10.1016/j.jpag.2009.03.007. 
  10. Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med. 2005 Dec 15;353(24):2578-88. doi: 10.1056/NEJMcp033496. 
  11. Mayo Clinic. Polycystic ovary syndrome (PCOS). Available from:  https://www.mayoclinic.org/diseases-conditions/pcos/diagnosis-treatment/...
  12. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD007506. doi: 10.1002/14651858.CD007506.pub3. Update in: Cochrane Database Syst Rev. 2019 Mar 28;3:CD007506. 
  13. Practice Committee of the American Society for Reproductive Medicine. The evaluation and treatment of androgen excess. Fertil Steril. 2006 Nov;86(5 Suppl 1):S241-7. doi: 10.1016/j.fertnstert.2006.08.042. 
  14. Orfanos CE, Adler YD, Zouboulis CC. The SAHA syndrome. Horm Res. 2000;54(5-6):251-8. doi: 10.1159/000053267. 
  15. New MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2006 Nov;91(11):4205-14. doi: 10.1210/jc.2006-1645. Epub 2006 Aug 15. Erratum in: J Clin Endocrinol Metab. 2007 Jan;92(1):142. Dosage error in article text. PMID: 16912124.
  16. Loriaux DL. An approach to the patient with hirsutism. J Clin Endocrinol Metab. 2012 Sep;97(9):2957-68. doi: 10.1210/jc.2011-2744.
  17. Somani N, Harrison S, Bergfeld WF. The clinical evaluation of hirsutism. Dermatol Ther. 2008 Sep-Oct;21(5):376-91. doi: 10.1111/j.1529-8019.2008.00219.x.
  18. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, Shapiro J, Montori VM, Swiglo BA. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008 Apr;93(4):1105-20. doi: 10.1210/jc.2007-2437. Epub 2008 Feb 5. Erratum in: J Clin Endocrinol Metab. 2021 Jun 16;106(7):e2845. 
  19. Kahraman K, Sükür YE, Atabekoğlu CS, Ateş C, Taşkın S, Cetinkaya SE, Tolunay HE, Ozmen B, Sönmezer M, Berker B. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. Arch Gynecol Obstet. 2014 Aug;290(2):321-8. doi: 10.1007/s00404-014-3217-5. 
  20. Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev. 2003;2003(4):CD001125. doi: 10.1002/14651858.CD001125. 
  21. Cosma M, Swiglo BA, Flynn DN, Kurtz DM, Labella ML, Mullan RJ, Elamin MB, Erwin PJ, Montori VM. Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab. 2008 Apr;93(4):1135-42. doi: 10.1210/jc.2007-2429. 
  22. Spritzer P, Billaud L, Thalabard JC, Birman P, Mowszowicz I, Raux-Demay MC, Clair F, Kuttenn F, Mauvais-Jarvis P. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J Clin Endocrinol Metab. 1990 Mar;70(3):642-6. doi: 10.1210/jcem-70-3-642. 
  23. Somani N, Turvy D. Hirsutism: an evidence-based treatment update. Am J Clin Dermatol. 2014 Jul;15(3):247-66. doi: 10.1007/s40257-014-0078-4. PMID: 24889738.

Download Article
Received April 19, 2022.
Accepted May 24, 2022.
©2022 International Medical Research and Development Corporation.